Details of the Drug Combination

General Information of Drug Combination (ID: DCDWTBN)

Drug Combination Name
Sunitinib malate Piperacetazine
Indication
Disease Entry Status REF
Hepatocellular carcinoma Investigative [1]
Component Drugs Sunitinib malate   DMN8E5D Piperacetazine   DMGQU0Y
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: Huh-7
Zero Interaction Potency (ZIP) Score: 6.312
Bliss Independence Score: 7.44
Loewe Additivity Score: 3.061
LHighest Single Agent (HSA) Score: 12.078

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Sunitinib malate Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [3]
------------------------------------------------------------------------------------
Indication(s) of Piperacetazine
Disease Entry ICD 11 Status REF
Schizophrenia 6A20 Approved [2]
Piperacetazine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Modulator [4]
------------------------------------------------------------------------------------
Piperacetazine Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [5]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
3 JNK-AKT-NF-kB controls P-glycoprotein expression to attenuate the cytotoxicity of deoxynivalenol in mammalian cells. Biochem Pharmacol. 2018 Oct;156:120-134.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.